Clinical Research Directory
Browse clinical research sites, groups, and studies.
Immunosuppressant Withdrawal Based on Parenchymal Chimerism in the Liver Transplantation
Sponsor: Chang Gung Memorial Hospital
Summary
The goal of this clinical trial is to learn whether liver parenchyma chimerism can represent a chievement of operational tolerance in liver transplantation recipients. The researchers will examine the degree of parenchyma chimerism. The participants will withdraw or minimize their immunosuppression to avoid the adverse effects of immunosuppressants.
Official title: The Investigation of Transplant Tolerance and Immunosuppressant Withdrawal Based on Parenchymal Chimerism in the Liver
Key Details
Gender
All
Age Range
20 Years - Any
Study Type
INTERVENTIONAL
Enrollment
60
Start Date
2025-08-01
Completion Date
2027-07-31
Last Updated
2026-07-30
Healthy Volunteers
No
Interventions
liver biopsy
Liver tissue will be obtained to perform short tandem repeat (STR) analysis to determine the degree of parenchymal chimerism.
Immunosuppression withdrawal
For patients with an STR $\\ge$ 75% percentile cutoff, half dose of the immunosuppressive regimen is decreased for the first two months. If liver function is unaltered, immunosuppression is totally withdrawn at the 3rd month.
Immunosuppression minimization
For patients with STR \> 15% but not reaching the 75% percentile cutoff, the immunosuppressive regimen is decreased by 1/3 at the first two months. If liver function is unaltered, it is further decreased to 1/2 of the original dose.
Locations (1)
Chang-Gung Memorial Hospital
Taoyuan, Taiwan